Search

Your search keyword '"Wacholder, Sholom"' showing total 1,447 results
Start Over Author "Wacholder, Sholom"
1,447 results on '"Wacholder, Sholom"'

1. Risk Factors for Non–Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA–Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial

Author

Sierra, Mónica S, Tsang, Sabrina H, Hu, Shangying, Porras, Carolina, Herrero, Rolando, Kreimer, Aimée R, Schussler, John, Boland, Joseph, Wagner, Sarah, Cortes, Bernal, Rodríguez, Ana C, Quint, Wim, van Doorn, Leen-Jan, Schiffman, Mark, Sampson, Joshua N, Hildesheim, Allan, Cortés, Bernal, González, Paula, Jiménez, Silvia E, Rodríguez, Ana Cecilia, Lowy, Douglas R, Schiller, John T, Sherman, Mark, Wacholder, Sholom, Pinto, Ligia A, Kemp, Troy J, Sidawy, Mary K, Struijk, Linda, Palefsky, Joel M, Darragh, Teresa M, and Stoler, Mark H

Subjects
Clinical Research, Behavioral and Social Science, Clinical Trials and Supportive Activities, Sexually Transmitted Infections, HPV and/or Cervical Cancer Vaccines, Immunization, Prevention, HIV/AIDS, Cervical Cancer, Adolescent Sexual Activity, Infectious Diseases, Vaccine Related, Pediatric, Cancer, Adolescent, Adult, Cervical Intraepithelial Neoplasia, Costa Rica, DNA, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Pregnancy, Risk Factors, Treatment Outcome, Uterine Cervical Neoplasms, Young Adult, Costa Rica Human Papillomavirus Vaccine Trial (CVT) Group, Uterine Cervical Dysplasia, CIN2+, HPV infection, HPV vaccine, incidence, persistence, progression, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundFactors that lead human papillomavirus (HPV) infections to persist and progress to cancer are not fully understood. We evaluated co-factors for acquisition, persistence, and progression of non-HPV-16/18 infections among HPV-vaccinated women.MethodsWe analyzed 2153 women aged 18-25 years randomized to the HPV-vaccine arm of the Costa Rica HPV Vaccine Trial. Women were HPV DNA negative for all types at baseline and followed for approximately 11 years. Generalized estimating equation methods were used to account for correlated observations. Time-dependent factors evaluated were age, sexual behavior, marital status, hormonally related factors, number of full-term pregnancies (FTPs), smoking behavior, and baseline body mass index.ResultsA total of 1777 incident oncogenic non-HPV-16/18 infections were detected in 12 292 visits (average, 0.14 infections/visit). Age and sexual behavior-related variables were associated with oncogenic non-HPV-16/18 acquisition. Twenty-six percent of incident infections persisted for ≥1 year. None of the factors evaluated were statistically associated with persistence of oncogenic non-HPV-16/18 infections. Risk of progression to Cervical Intraepithelial Neoplasia grade 2 or worst (CIN2+) increased with increasing age (P for trend = .001), injectable contraceptive use (relative risk, 2.61 [95% confidence interval, 1.19-5.73] ever vs never), and increasing FTPs (P for trend = .034).ConclusionsIn a cohort of HPV-16/18-vaccinated women, age and sexual behavior variables are associated with acquisition of oncogenic non-HPV-16/18 infections; no notable factors are associated with persistence of acquired infections; and age, parity, and hormonally related exposures are associated with progression to CIN2+.

Published
2021

2. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine: Pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials

Author

Tota, Joseph E, Struyf, Frank, Sampson, Joshua N, Gonzalez, Paula, Ryser, Martin, Herrero, Rolando, Schussler, John, Karkada, Naveen, Rodriguez, Ana Cecilia, Folschweiller, Nicolas, Porras, Carolina, Schiffman, Mark, Schiller, John T, Quint, Wim, Kreimer, Aimée R, Wheeler, Cosette M, Hildesheim, Allan, Cortés, Bernal, González, Paula, Jiménez, Silvia E, Rodríguez, Ana Cecilia, Lowy, Douglas R, Wacholder, Sholom, Pinto, Ligia A, Kemp, Troy J, van Doorn, Leen-Jan, Struijk, Linda, Palefsky, Joel M, Darragh, Teresa M, Stoler, Mark H, Garland, SM, Skinner, SR, De Sutter, P, Poppe, WAJ, De Carvalho, NS, Teixeira, JC, Ferguson, L, Ferguson, M, Papp, K, Ramjattan, B, Orr, PH, Paavonen, J, Höpker, WD, Tobgui, S Jensen-El, Liverani, CA, Limson, GM, Marti, M Campins, Castro, M, Centeno, C, Chow, SN, Angsuwathana, S, Lewis, D, Ackerman, R, Caldwell, M, Chambers, C, Chatterjee, A, Harper, D, Sperling, R, Stapleton, J, Waldbaum, A, Lee, P, and Awedikian, Rafi

Subjects
Sexually Transmitted Infections, Immunization, Cancer, Biotechnology, Infectious Diseases, HPV and/or Cervical Cancer Vaccines, Vaccine Related, Clinical Research, Clinical Trials and Supportive Activities, Cervical Cancer, Prevention, HIV/AIDS, Adjuvants, Immunologic, Adolescent, Adult, Costa Rica, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomavirus Infections, Papillomavirus Vaccines, Randomized Controlled Trials as Topic, Retrospective Studies, Treatment Outcome, Uterine Cervical Neoplasms, Young Adult, Uterine Cervical Dysplasia, Costa Rica Vaccine Trial and PATRICIA Study, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThe AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower levels of protection may exist for a wide range of oncogenic HPV types, which is difficult to quantify in individual trials. Pooling individual-level data from two randomized controlled trials, we aimed to evaluate AS04-HPV16/18 vaccine efficacy against incident HPV infections and cervical abnormalities .MethodsData were available from the Costa Rica Vaccine Trial (NCT00128661) and Papilloma Trial Against Cancer in Young Adults trial (NCT00122681), two large-scale, double-blind randomized controlled trials of the AS04-HPV16/18 vaccine. Primary analyses focused on disease-free women with no detectable cervicovaginal HPV at baseline.ResultsA total of 12 550 women were included in our primary analyses (HPV arm = 6271, control arm = 6279). Incidence of 6-month persistent oncogenic and nononcogenic infections, excluding known and accepted protected types 6/11/16/18/31/33/45 (focusing on 34/35/39/40/42/43/44/51/52/53/54/56/58/59/66/68/73/70/74), was statistically significantly lower in the HPV arm than in the control arm (efficacy = 9.9%, 95% confidence interval [CI] = 1.7% to 17.4%). Statistically significant efficacy (P

Published
2020

3. Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes

Author

Wagner, Sarah, Roberson, David, Boland, Joseph, Kreimer, Aimée R, Yeager, Meredith, Cullen, Michael, Mirabello, Lisa, Dunn, S Terence, Walker, Joan, Zuna, Rosemary, Porras, Carolina, Cortes, Bernal, Sampson, Joshua, Herrero, Rolando, Rodriguez, Ana Cecilia, Quint, Wim, Van Doorn, Leen-Jan, José, San, González, Paula, Jiménez, Silvia E, Rodríguez, Ana Cecilia, Hildesheim, Allan, Lowy, Douglas R, Schiffman, Mark, Schiller, John T, Sherman, Mark, Wacholder, Sholom, Pinto, Ligia A, Kemp, Troy J, Sidawy, Mary K, van Doorn, Leen-Jan, Struijk, Linda, Palefsky, Joel M, Darragh, Teresa M, Stoler, Mark H, and Wentzensen, Nicolas

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Biological Sciences, Infectious Diseases, Prevention, Vaccine Related, Cervical Cancer, Biotechnology, Genetics, Cancer, HIV/AIDS, Sexually Transmitted Infections, Immunization, Adolescent, Adult, Aged, Aged, 80 and over, Costa Rica, Costs and Cost Analysis, Cross-Sectional Studies, Female, Genotype, Genotyping Techniques, High-Throughput Nucleotide Sequencing, Humans, Middle Aged, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Young Adult, HPV, TypeSeq, vaccine efficacy, genotyping, screening, CVT Group, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundHuman papillomaviruses (HPV) cause over 500 000 cervical cancers each year, most of which occur in low-resource settings. Human papillomavirus genotyping is important to study natural history and vaccine efficacy. We evaluated TypeSeq, a novel, next-generation, sequencing-based assay that detects 51 HPV genotypes, in 2 large international epidemiologic studies.MethodsTypeSeq was evaluated in 2804 cervical specimens from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEED) and in 2357 specimens from the Costa Rica Vaccine Trial (CVT). Positive agreement and risks of precancer for individual genotypes were calculated for TypeSeq in comparison to Linear Array (SUCCEED). In CVT, positive agreement and vaccine efficacy were calculated for TypeSeq and SPF10-LiPA.ResultsWe observed high overall and positive agreement for most genotypes between TypeSeq and Linear Array in SUCCEED and SPF10-LiPA in CVT. There was no significant difference in risk of precancer between TypeSeq and Linear Array in SUCCEED or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT.ConclusionsThe agreement of TypeSeq with Linear Array and SPF10-LiPA, 2 well established standards for HPV genotyping, demonstrates its high accuracy. TypeSeq provides high-throughput, affordable HPV genotyping for world-wide studies of cervical precancer risk and of HPV vaccine efficacy.

Published
2019

4. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial

Author

Cortés, Bernal, González, Paula, Herrero, Rolando, Jiménez, Silvia E., Porras, Carolina, Rodríguez, Ana Cecilia, Hildesheim, Allan, Kreimer, Aimée R., Lowy, Douglas R., Schiffman, Mark, Schiller, John T., Sherman, Mark, Wacholder, Sholom, Pinto, Ligia A., Kemp, Troy J., Sidawy, Mary K., Quint, Wim, van Doorn, Leen-Jan, Struijk, Linda, Palefsky, Joel M., Darragh, Teresa M., Stoler, Mark H., Shing, Jaimie Z, Hu, Shangying, Sampson, Joshua N, Schussler, John, Schiller, John T, Lowy, Douglas R, Sierra, Mónica S, Carvajal, Loretto, and Kreimer, Aimée R

Published
2022
Full Text
View/download PDF

5. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial

Author

Safaeian, Mahboobeh, Sampson, Joshua N, Pan, Yuanji, Porras, Carolina, Kemp, Troy J, Herrero, Rolando, Quint, Wim, van Doorn, Leen Jan, Schussler, John, Lowy, Douglas R, Schiller, John, Schiffman, Mark T, Rodriguez, Ana Cecilia, Gail, Mitchell H, Hildesheim, Allan, Gonzalez, Paula, Pinto, Ligia A, Kreimer, Aimée R, Paula, González, Jiménez, Silvia E, Rodríguez, Ana Cecilia, Schiffman, Mark, Schiller, John T, Sherman, Mark, Wacholder, Sholom, Sidawy, Mary K, van Doorn, Leen-Jan, Struijk, Linda, Palefsky, Joel M, Darragh, Teresa M, and Stoler, Mark H

Subjects
Immunization, Prevention, HPV and/or Cervical Cancer Vaccines, Biotechnology, Clinical Trials and Supportive Activities, Cervical Cancer, Clinical Research, Vaccine Related, Infectious Diseases, Sexually Transmitted Infections, Cancer, HIV/AIDS, Infection, Adolescent, Adult, Antibodies, Viral, Cervix Uteri, DNA, Viral, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Diseases, Young Adult, Costa Rica HPV Vaccine Trial (CVT) Group, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group.

Published
2018

6. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Author

Hildesheim, Allan, Gonzalez, Paula, Kreimer, Aimee, Wacholder, Sholom, Schussler, John, Rodriguez, Ana, Porras, Carolina, Schiffman, Mark, Sidawy, Mary, Schiller, John, Lowy, Douglas, and Herrero, Rolando

Subjects
cervical cancer, clinical trial, human papillomaviruses, prevention, vaccines, Adolescent, Adult, Cervix Uteri, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Incidence, Papillomavirus Infections, Papillomavirus Vaccines, Prevalence, Treatment Outcome, Uterine Cervical Neoplasms, Vaccination, Young Adult, Uterine Cervical Dysplasia
Abstract

BACKGROUND: Human papillomavirus vaccines prevent human papillomavirus infection and cervical precancers. The impact of vaccinating women with a current infection or after treatment for an human papillomavirus-associated lesion is not fully understood. OBJECTIVES: To determine whether human papillomavirus-16/18 vaccination influences the outcome of infections present at vaccination and the rate of infection and disease after treatment of lesions. STUDY DESIGN: We included 1711 women (18-25 years) with carcinogenic human papillomavirus infection and 311 women of similar age who underwent treatment for cervical precancer and who participated in a community-based trial of the AS04-adjuvanted human papillomavirus-16/18 virus-like particle vaccine. Participants were randomized (human papillomavirus or hepatitis A vaccine) and offered 3 vaccinations over 6 months. Follow-up included annual visits (more frequently if clinically indicated), referral to colposcopy of high-grade and persistent low-grade lesions, treatment by loop electrosurgical excisional procedure when clinically indicated, and cytologic and virologic follow-up after treatment. Among women with human papillomavirus infection at the time of vaccination, we considered type-specific viral clearance, and development of cytologic (squamous intraepithelial lesions) and histologic (cervical intraepithelial neoplasia) lesions. Among treated women, we considered single-time and persistent human papillomavirus infection, squamous intraepithelial lesions, and cervical intraepithelial neoplasia 2 or greater. Outcomes associated with infections absent before treatment also were evaluated. Infection-level analyses were performed and vaccine efficacy estimated. RESULTS: Median follow-up was 56.7 months (women with human papillomavirus infection) and 27.3 months (treated women). There was no evidence of vaccine efficacy to increase clearance of human papillomavirus infections or decrease incidence of cytologic/histologic abnormalities associated with human papillomavirus types present at enrollment. Vaccine efficacy for human papillomavirus 16/18 clearance and against human papillomavirus 16/18 progression from infection to cervical intraepithelial neoplasia 2 or greater were -5.4% (95% confidence interval -19,10) and 0.3% (95% confidence interval -69,41), respectively. Among treated women, 34.1% had oncogenic infection and 1.6% had cervical intraepithelial neoplasia 2 or greater detected after treatment, respectively, and of these 69.8% and 20.0% were the result of new infections. We observed no significant effect of vaccination on rates of infection/lesions after treatment. Vaccine efficacy estimates for human papillomavirus 16/18 associated persistent infection and cervical intraepithelial neoplasia 2 or greater after treatment were 34.7% (95% confidence interval -131, 82) and -211% (95% confidence interval -2901, 68), respectively. We observed evidence for a partial and nonsignificant protective effect of vaccination against new infections absent before treatment. For incident human papillomavirus 16/18, human papillomavirus 31/33/45, and oncogenic human papillomavirus infections post-treatment, vaccine efficacy estimates were 57.9% (95% confidence interval -43, 88), 72.9% (95% confidence interval 29, 90), and 36.7% (95% confidence interval 1.5, 59), respectively. CONCLUSION: We find no evidence for a vaccine effect on the fate of detectable human papillomavirus infections. We show that vaccination does not protect against infections/lesions after treatment. Evaluation of vaccine protection against new infections after treatment and resultant lesions warrants further consideration in future studies.

Published
2016

7. Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

Author

Harari, Ariana, Chen, Zigui, Rodríguez, Ana, Hildesheim, Allan, Porras, Carolina, Herrero, Rolando, Wacholder, Sholom, Panagiotou, Orestis, Befano, Brian, Burk, Robert, and Schiffman, Mark

Subjects
HPV vaccine, HPV variants, cross-protection, Adolescent, Adult, Double-Blind Method, Female, Genetic Variation, Humans, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Young Adult
Abstract

BACKGROUND: Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. METHODS: A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for

Published
2016

8. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial.

Author

Panagiotou, Orestis A, Befano, Brian L, Gonzalez, Paula, Rodríguez, Ana Cecilia, Herrero, Rolando, Schiller, John T, Kreimer, Aimée R, Schiffman, Mark, Hildesheim, Allan, Wilcox, Allen J, Wacholder, Sholom, and Costa Rica HPV Vaccine Trial (CVT) Group (see end of manuscript for full list of investigators)

Subjects
Costa Rica HPV Vaccine Trial (CVT) Group, Humans, Abortion, Spontaneous, Pregnancy Outcome, Follow-Up Studies, Double-Blind Method, Maternal Age, Gestational Age, Pregnancy, Adolescent, Adult, Costa Rica, Female, Papillomavirus Vaccines, Young Adult, Clinical Trials and Supportive Activities, HPV and/or Cervical Cancer Vaccines, Vaccine Related, Clinical Research, Immunization, Infectious Diseases, Sexually Transmitted Infections, Cancer, Prevention, 3.4 Vaccines, Infection, Reproductive health and childbirth, General & Internal Medicine, Clinical Sciences, Public Health and Health Services
Abstract

OBJECTIVE:To examine the effect of the bivalent human papillomavirus (HPV) vaccine on miscarriage. DESIGN:Observational long term follow-up of a randomized, double blinded trial combined with an independent unvaccinated population based cohort. SETTING:Single center study in Costa Rica. PARTICIPANTS:7466 women in the trial and 2836 women in the unvaccinated cohort enrolled at the end of the randomized trial and in parallel with the observational trial component. INTERVENTION:Women in the trial were assigned to receive three doses of bivalent HPV vaccine (n=3727) or the control hepatitis A vaccine (n=3739). Crossover bivalent HPV vaccination occurred in the hepatitis A vaccine arm at the end of the trial. Women in the unvaccinated cohort received (n=2836) no vaccination. MAIN OUTCOME MEASURE:Risk of miscarriage, defined by the US Centers for Disease Control and Prevention as fetal loss within 20 weeks of gestation, in pregnancies exposed to bivalent HPV vaccination in less than 90 days and any time from vaccination compared with pregnancies exposed to hepatitis A vaccine and pregnancies in the unvaccinated cohort. RESULTS:Of 3394 pregnancies conceived at any time since bivalent HPV vaccination, 381 pregnancies were conceived less than 90 days from vaccination. Unexposed pregnancies comprised 2507 pregnancies conceived after hepatitis A vaccination and 720 conceived in the unvaccinated cohort. Miscarriages occurred in 451 (13.3%) of all exposed pregnancies, in 50 (13.1%) of the pregnancies conceived less than 90 days from bivalent HPV vaccination, and in 414 (12.8%) of the unexposed pregnancies, of which 316 (12.6%) were in the hepatitis A vaccine group and 98 (13.6%) in the unvaccinated cohort. The relative risk of miscarriage for pregnancies conceived less than 90 days from vaccination compared with all unexposed pregnancies was 1.02 (95% confidence interval 0.78 to 1.34, one sided P=0.436) in unadjusted analyses. Results were similar after adjusting for age at vaccination (relative risk 1.15, one sided P=0.17), age at conception (1.03, P=0.422), and calendar year (1.06, P=0.358), and in stratified analyses. Among pregnancies conceived at any time from bivalent HPV vaccination, exposure was not associated with an increased risk of miscarriage overall or in subgroups, except for miscarriages at weeks 13-20 of gestation (relative risk 1.35, 95% confidence interval 1.02 to 1.77, one sided P=0.017). CONCLUSIONS:There is no evidence that bivalent HPV vaccination affects the risk of miscarriage for pregnancies conceived less than 90 days from vaccination. The increased risk estimate for miscarriages in a subgroup of pregnancies conceived any time after vaccination may be an artifact of a thorough set of sensitivity analyses, but since a genuine association cannot totally be ruled out, this signal should nevertheless be explored further in existing and future studies.Trial registration Clinicaltrials.gov NCT00128661 and NCT01086709.

Published
2015

9. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.

Author

Gonzalez, Paula, Hildesheim, Allan, Herrero, Rolando, Katki, Hormuzd, Wacholder, Sholom, Porras, Carolina, Safaeian, Mahboobeh, Jimenez, Silvia, Schiller, John, Ocampo, Rebeca, Schussler, John, Lowy, Douglas, Guillen, Diego, Stoler, Mark, Quint, Wim, Morales, Jorge, Avila, Carlos, Rodriguez, Ana, Kreimer, Aimée, Cortes, Bernal, Befano, Brian, Schiffman, Mark, Carvajal, Loreto, Palefsky, Joel, and Darragh, Teresa

Subjects
Human papillomavirus, Long term follow-up, Methods, Vaccines, Adult, Costa Rica, Cross-Over Studies, Early Detection of Cancer, Female, Follow-Up Studies, Hepatitis A Vaccines, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomavirus Infections, Papillomavirus Vaccines, Research Design, Time Factors, Uterine Cervical Diseases, Uterine Cervical Neoplasms, Vaccination, Young Adult, Uterine Cervical Dysplasia
Abstract

The Costa Rica Vaccine Trial (CVT) was a randomized clinical trial conducted between 2004 and 2010, which randomized 7466 women aged 18 to 25 to receive the bivalent HPV-16/18 vaccine or control Hepatitis-A vaccine. Participants were followed for 4 years with cross-over vaccination at the study end. In 2010 the long term follow-up (LTFU) study was initiated to evaluate the 10-year impact of HPV-16/18 vaccination, determinants of the immune response, and HPV natural history in a vaccinated population. Herein, the rationale, design and methods of the LTFU study are described, which actively follows CVT participants in the HPV-arm 6 additional years at biennial intervals (3 additional study visits for 10 years of total follow-up), or more often if clinically indicated. According to the initial commitment, women in the Hepatitis-A arm were offered HPV vaccination at cross-over; they were followed 2 additional years and exited from the study. 92% of eligible CVT women accepted participation in LTFU. To provide underlying rates of HPV acquisition and cervical disease among unvaccinated women to compare with the HPV-arm during LTFU, a new unvaccinated control group (UCG) of women who are beyond the age generally recommended for routine vaccination was enrolled, and will be followed by cervical cancer screening over 6 years. To form the UCG, 5000 women were selected from a local census, of whom 2836 women (61% of eligible women) agreed to participate. Over 90% of participants complied with an interview, blood and cervical specimen collection. Evaluation of comparability between the original (Hepatitis-A arm of CVT) and new (UCG) control groups showed that womens characteristics, as well as their predicted future risk for cervical HPV acquisition, were similar, thus validating use of the UCG. LTFU is poised to comprehensively address many important questions related to long-term effects of prophylactic HPV vaccines.

Published
2015

11. Breast Cancer Risks for BRCA1/2 Carriers

Author

Easton, Douglas F., Hopper, John L., Thomas, Duncan C., Antoniou, Antonis, Whittemore, Alice S., Haile, Robert W., Wacholder, Sholom, Struewing, Jeffery P., Hartge, Patricia, Greene, Mark H., Tucker, Margaret A., and King, Mary-Claire

Published
2004

12. Applying New Biotechnologies to the Study of Occupational Cancer: A Workshop Summary

Author

Toraason, Mark, Albertini, Richard, Bayard, Steven, Bigbee, William, Blair, Aaron, Boffetta, Paolo, Bonassi, Stefano, Chanock, Steven, Christiani, David, Eastmond, David, Hanash, Samuel, Henry, Carol, Kadlubar, Fred, Mirer, Frank, Nebert, Daniel, Rapport, Stephen, Rest, Kathleen, Rothman, Nathaniel, Ruder, Avima, Savage, Russell, Schulte, Paul, Siemiatycki, Jack, Shields, Peter, Smith, Martyn, Tolbert, Paige, Vermeulen, Roel, Vineis, Paolo, Wacholder, Sholom, Ward, Elizabeth, Waters, Michael, and Weston, Ainsley

Published
2004

22. Data from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

24. Data from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Author

Safaeian, Mahboobeh, primary, Porras, Carolina, primary, Pan, Yuanji, primary, Kreimer, Aimee, primary, Schiller, John T., primary, Gonzalez, Paula, primary, Lowy, Douglas R., primary, Wacholder, Sholom, primary, Schiffman, Mark, primary, Rodriguez, Ana C., primary, Herrero, Rolando, primary, Kemp, Troy, primary, Shelton, Gloriana, primary, Quint, Wim, primary, van Doorn, Leen-Jan, primary, Hildesheim, Allan, primary, and Pinto, Ligia A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 3 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

26. Interview with Dr. Herrero from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

Author

Herrero, Rolando, primary, Wacholder, Sholom, primary, Rodríguez, Ana C., primary, Solomon, Diane, primary, González, Paula, primary, Kreimer, Aimee R., primary, Porras, Carolina, primary, Schussler, John, primary, Jiménez, Silvia, primary, Sherman, Mark E., primary, Quint, Wim, primary, Schiller, John T., primary, Lowy, Douglas R., primary, Schiffman, Mark, primary, and Hildesheim, Allan, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 1 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables 1-11 from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

Author

Herrero, Rolando, primary, Wacholder, Sholom, primary, Rodríguez, Ana C., primary, Solomon, Diane, primary, González, Paula, primary, Kreimer, Aimee R., primary, Porras, Carolina, primary, Schussler, John, primary, Jiménez, Silvia, primary, Sherman, Mark E., primary, Quint, Wim, primary, Schiller, John T., primary, Lowy, Douglas R., primary, Schiffman, Mark, primary, and Hildesheim, Allan, primary

Published
2023
Full Text
View/download PDF

29. Data from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

Author

Herrero, Rolando, primary, Wacholder, Sholom, primary, Rodríguez, Ana C., primary, Solomon, Diane, primary, González, Paula, primary, Kreimer, Aimee R., primary, Porras, Carolina, primary, Schussler, John, primary, Jiménez, Silvia, primary, Sherman, Mark E., primary, Quint, Wim, primary, Schiller, John T., primary, Lowy, Douglas R., primary, Schiffman, Mark, primary, and Hildesheim, Allan, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Material 2 from A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma

Author

Rotunno, Melissa, primary, Hu, Nan, primary, Su, Hua, primary, Wang, Chaoyu, primary, Goldstein, Alisa M., primary, Bergen, Andrew W., primary, Consonni, Dario, primary, Pesatori, Angela C., primary, Bertazzi, Pier Alberto, primary, Wacholder, Sholom, primary, Shih, Joanna, primary, Caporaso, Neil E., primary, Taylor, Phil R., primary, and Landi, Maria Teresa, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 6 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 5 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

34. Data from A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma

Author

Rotunno, Melissa, primary, Hu, Nan, primary, Su, Hua, primary, Wang, Chaoyu, primary, Goldstein, Alisa M., primary, Bergen, Andrew W., primary, Consonni, Dario, primary, Pesatori, Angela C., primary, Bertazzi, Pier Alberto, primary, Wacholder, Sholom, primary, Shih, Joanna, primary, Caporaso, Neil E., primary, Taylor, Phil R., primary, and Landi, Maria Teresa, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figures 1 - 11 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures and Tables from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Author

Safaeian, Mahboobeh, primary, Porras, Carolina, primary, Pan, Yuanji, primary, Kreimer, Aimee, primary, Schiller, John T., primary, Gonzalez, Paula, primary, Lowy, Douglas R., primary, Wacholder, Sholom, primary, Schiffman, Mark, primary, Rodriguez, Ana C., primary, Herrero, Rolando, primary, Kemp, Troy, primary, Shelton, Gloriana, primary, Quint, Wim, primary, van Doorn, Leen-Jan, primary, Hildesheim, Allan, primary, and Pinto, Ligia A., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 2 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 4 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Author

Mirabello, Lisa, primary, Koster, Roelof, primary, Moriarity, Branden S., primary, Spector, Logan G., primary, Meltzer, Paul S., primary, Gary, Joy, primary, Machiela, Mitchell J., primary, Pankratz, Nathan, primary, Panagiotou, Orestis A., primary, Largaespada, David, primary, Wang, Zhaoming, primary, Gastier-Foster, Julie M., primary, Gorlick, Richard, primary, Khanna, Chand, primary, de Toledo, Silvia Regina Caminada, primary, Petrilli, Antonio S., primary, Patiño-Garcia, Ana, primary, Sierrasesúmaga, Luis, primary, Lecanda, Fernando, primary, Andrulis, Irene L., primary, Wunder, Jay S., primary, Gokgoz, Nalan, primary, Serra, Massimo, primary, Hattinger, Claudia, primary, Picci, Piero, primary, Scotlandi, Katia, primary, Flanagan, Adrienne M., primary, Tirabosco, Roberto, primary, Amary, Maria Fernanda, primary, Halai, Dina, primary, Ballinger, Mandy L., primary, Thomas, David M., primary, Davis, Sean, primary, Barkauskas, Donald A., primary, Marina, Neyssa, primary, Helman, Lee, primary, Otto, George M., primary, Becklin, Kelsie L., primary, Wolf, Natalie K., primary, Weg, Madison T., primary, Tucker, Margaret, primary, Wacholder, Sholom, primary, Fraumeni, Joseph F., primary, Caporaso, Neil E., primary, Boland, Joseph F., primary, Hicks, Belynda D., primary, Vogt, Aurelie, primary, Burdett, Laurie, primary, Yeager, Meredith, primary, Hoover, Robert N., primary, Chanock, Stephen J., primary, and Savage, Sharon A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Material 1 from A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma

Author

Rotunno, Melissa, primary, Hu, Nan, primary, Su, Hua, primary, Wang, Chaoyu, primary, Goldstein, Alisa M., primary, Bergen, Andrew W., primary, Consonni, Dario, primary, Pesatori, Angela C., primary, Bertazzi, Pier Alberto, primary, Wacholder, Sholom, primary, Shih, Joanna, primary, Caporaso, Neil E., primary, Taylor, Phil R., primary, and Landi, Maria Teresa, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 3 from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

41. Data from A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study

Author

Schiffman, Mark, primary, Glass, Andrew G., primary, Wentzensen, Nicolas, primary, Rush, Brenda B., primary, Castle, Philip E., primary, Scott, David R., primary, Buckland, Julie, primary, Sherman, Mark E., primary, Rydzak, Greg, primary, Kirk, Peter, primary, Lorincz, Attila T., primary, Wacholder, Sholom, primary, and Burk, Robert D., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 2A from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Tables 1-2 from A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study

Author

Schiffman, Mark, primary, Glass, Andrew G., primary, Wentzensen, Nicolas, primary, Rush, Brenda B., primary, Castle, Philip E., primary, Scott, David R., primary, Buckland, Julie, primary, Sherman, Mark E., primary, Rydzak, Greg, primary, Kirk, Peter, primary, Lorincz, Attila T., primary, Wacholder, Sholom, primary, and Burk, Robert D., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table Legends from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

46. Data from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Tables 3-4 from A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study

Author

Schiffman, Mark, primary, Glass, Andrew G., primary, Wentzensen, Nicolas, primary, Rush, Brenda B., primary, Castle, Philip E., primary, Scott, David R., primary, Buckland, Julie, primary, Sherman, Mark E., primary, Rydzak, Greg, primary, Kirk, Peter, primary, Lorincz, Attila T., primary, Wacholder, Sholom, primary, and Burk, Robert D., primary

Published
2023
Full Text
View/download PDF

48. Data from Genetic Variation at the CYP19A1 Locus Predicts Circulating Estrogen Levels but not Breast Cancer Risk in Postmenopausal Women

Author

Haiman, Christopher A., primary, Dossus, Laure, primary, Setiawan, V. Wendy, primary, Stram, Daniel O., primary, Dunning, Alison M., primary, Thomas, Gilles, primary, Thun, Michael J., primary, Albanes, Demetrius, primary, Altshuler, David, primary, Ardanaz, Eva, primary, Boeing, Heiner, primary, Buring, Julie, primary, Burtt, Noël, primary, Calle, Eugenia E., primary, Chanock, Stephen, primary, Clavel-Chapelon, Françoise, primary, Colditz, Graham A., primary, Cox, David G., primary, Feigelson, Heather Spencer, primary, Hankinson, Susan E., primary, Hayes, Richard B., primary, Henderson, Brian E., primary, Hirschhorn, Joel N., primary, Hoover, Robert, primary, Hunter, David J., primary, Kaaks, Rudolf, primary, Kolonel, Laurence N., primary, Le Marchand, Loïc, primary, Lenner, Per, primary, Lund, Eiliv, primary, Panico, Salvatore, primary, Peeters, Petra H., primary, Pike, Malcolm C., primary, Riboli, Elio, primary, Tjonneland, Anne, primary, Travis, Ruth, primary, Trichopoulos, Dimitrios, primary, Wacholder, Sholom, primary, and Ziegler, Regina G., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Methods and Tables 1-4 from Genetic Variation at the CYP19A1 Locus Predicts Circulating Estrogen Levels but not Breast Cancer Risk in Postmenopausal Women

Author

Haiman, Christopher A., primary, Dossus, Laure, primary, Setiawan, V. Wendy, primary, Stram, Daniel O., primary, Dunning, Alison M., primary, Thomas, Gilles, primary, Thun, Michael J., primary, Albanes, Demetrius, primary, Altshuler, David, primary, Ardanaz, Eva, primary, Boeing, Heiner, primary, Buring, Julie, primary, Burtt, Noël, primary, Calle, Eugenia E., primary, Chanock, Stephen, primary, Clavel-Chapelon, Françoise, primary, Colditz, Graham A., primary, Cox, David G., primary, Feigelson, Heather Spencer, primary, Hankinson, Susan E., primary, Hayes, Richard B., primary, Henderson, Brian E., primary, Hirschhorn, Joel N., primary, Hoover, Robert, primary, Hunter, David J., primary, Kaaks, Rudolf, primary, Kolonel, Laurence N., primary, Le Marchand, Loïc, primary, Lenner, Per, primary, Lund, Eiliv, primary, Panico, Salvatore, primary, Peeters, Petra H., primary, Pike, Malcolm C., primary, Riboli, Elio, primary, Tjonneland, Anne, primary, Travis, Ruth, primary, Trichopoulos, Dimitrios, primary, Wacholder, Sholom, primary, and Ziegler, Regina G., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables 1S-7S, Figure 1S from Haplotype Analysis of the HSD17B1 Gene and Risk of Breast Cancer: A Comprehensive Approach to Multicenter Analyses of Prospective Cohort Studies

Author

Feigelson, Heather Spencer, primary, Cox, David G., primary, Cann, Howard M., primary, Wacholder, Sholom, primary, Kaaks, Rudolf, primary, Henderson, Brian E., primary, Albanes, Demetrius, primary, Altshuler, David, primary, Berglund, Goran, primary, Berrino, Franco, primary, Bingham, Sheila, primary, Buring, Julie E., primary, Burtt, Noel P., primary, Calle, Eugenia E., primary, Chanock, Stephen J., primary, Clavel-Chapelon, Francoise, primary, Colditz, Graham, primary, Diver, W. Ryan, primary, Freedman, Matthew L., primary, Haiman, Christopher A., primary, Hankinson, Susan E., primary, Hayes, Richard B., primary, Hirschhorn, Joel N., primary, Hunter, David, primary, Kolonel, Laurence N., primary, Kraft, Peter, primary, LeMarchand, Loic, primary, Linseisen, Jakob, primary, Modi, William, primary, Navarro, Carmen, primary, Peeters, Petra H., primary, Pike, Malcolm C., primary, Riboli, Elio, primary, Setiawan, V. Wendy, primary, Stram, Daniel O., primary, Thomas, Gilles, primary, Thun, Michael J., primary, Tjonneland, Anne, primary, and Trichopoulos, Dimitrios, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results